Conmed (CNMD) Cash & Equivalents (2010 - 2026)

Conmed (CNMD) has 17 years of Cash & Equivalents data on file, last reported at $35.0 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 1.28% year-over-year to $35.0 million; the trailing twelve-month figure through Mar 2026 stood at $35.0 million (down 1.28% YoY), and the FY2025 full-year result was $40.8 million, up 66.88% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $35.0 million, down from $40.8 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $53.2 million in Q2 2022 and bottomed at $24.3 million in Q4 2023.
• The 5-year median for Cash & Equivalents is $33.4 million (2022), against an average of $32.9 million.
• The widest annual swing landed in 2023, when Cash & Equivalents plunged 47.61%; it then soared 66.88% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $28.9 million in 2022, then retreated by 16.05% to $24.3 million in 2023, then climbed by 0.67% to $24.5 million in 2024, then jumped by 66.88% to $40.8 million in 2025, then dropped by 14.18% to $35.0 million in 2026.
• The last three Cash & Equivalents figures came in at $35.0 million (Q1 2026), $40.8 million (Q4 2025), and $38.9 million (Q3 2025), per Business Quant data.

Peer Comparison